

IPCS

INTERNATIONAL PROGRAMME ON CHEMICAL SAFETY

IPCS Harmonization Project

Guidance for Immunotoxicity Risk Assessment for Chemicals

IOMC

INTER-ORGANIZATION PROGRAMME FOR THE SOUND MANAGEMENT OF CHEMICALS

A cooperative agreement among FAO, ILO, UNDP, UNEP, UNIDO, UNITAR, WHO, World Bank and OECD



**World Health
Organization**

This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.

Harmonization Project Document No. 10

GUIDANCE FOR IMMUNOTOXICITY RISK ASSESSMENT FOR CHEMICALS

This project was conducted within the WHO/International Programme on Chemical Safety project on the Harmonization of Approaches to the Assessment of Risk from Exposure to Chemicals.

WHO Library Cataloguing-in-Publication Data

Guidance for immunotoxicity risk assessment for chemicals.

(IPCS harmonization project document ; no. 10)

1.Risk assessment. 2.Immunotoxins. 3.Immune system. 4.Chemicals – toxicity.
4.Environmental exposure. I.International Programme on Chemical Safety.
II.Series.

ISBN 978 92 4 150330 3

(NLM classification: QW 630.5.I3)

© World Health Organization 2012

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications—whether for sale or for non-commercial distribution—should be addressed to WHO Press through the WHO web site (www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.

Technically and linguistically edited by Marla Sheffer, Ottawa, Canada

Printed by the WHO Document Production Services, Geneva, Switzerland

TABLE OF CONTENTS

FOREWORD	viii
ACKNOWLEDGEMENTS	ix
CONTRIBUTORS	x
LIST OF ACRONYMS AND ABBREVIATIONS	xv
EXECUTIVE SUMMARY	xviii
1. INTRODUCTION TO THE GUIDANCE DOCUMENT	1
1.1 Purpose of this document	1
1.2 Scope	1
1.3 Contents	2
2. BACKGROUND	4
2.1 The immune system as a special case	4
2.2 The importance of immune challenge in detecting immunotoxicity	6
2.3 Dose–response relationships and thresholds	8
2.4 Induction of tolerance	9
2.5 The possibilities for adverse outcomes: immune stimulation, suppression and/or misregulation	10
2.6 The developing immune system	11
2.7 Early-life exposure/later-life effects	13
2.8 Current practices	14
2.9 Newer approaches	16
3. FRAMEWORK FOR IMMUNOTOXICITY RISK ASSESSMENT FOR CHEMICALS	17
3.1 Risk assessment	17
3.2 Application of risk assessment principles to immunotoxicity	19
3.3 General considerations for immunotoxicity risk assessment	20
3.3.1 Introduction	20
3.3.2 Clinical and epidemiological data	20
3.3.2.1 Clinical data	20
3.3.2.2 Epidemiological data	20
3.3.3 Laboratory animal data	22
3.3.3.1 Introduction	22
3.3.3.2 Considerations in evaluating immunotoxicity data	23
3.3.4 Local versus systemic effects	26
3.3.5 (Ir)reversibility of effects	27
3.3.6 Biological plausibility	27
3.3.6.1 Characterization of the health-related database	27
3.3.6.2 Weight of evidence evaluation of the health-related database	30

3.3.6.3	“Triggers” and the need for additional data to determine immunotoxicity hazard	32
3.3.7	Dose–response relationships and thresholds.....	34
3.3.7.1	Shape of the dose–response curve	34
3.3.7.2	Mode of action and dose metric.....	35
3.3.7.3	Dose–response analytical approaches.....	36
3.3.7.4	Dose–response risk assessment output: health-based guidance values	36
3.3.8	Groups at risk (developing immune system, elderly, immunocompromised)	37
3.3.9	Acute versus chronic exposure	38
3.3.10	Uncertainty factors.....	38
3.3.10.1	Intraspecies uncertainty factor	38
3.3.10.2	Interspecies uncertainty factor	39
3.3.10.3	LOAEL to NOAEL uncertainty factor	39
3.3.10.4	Subchronic to chronic uncertainty factor.....	40
3.3.10.5	Database uncertainty factor.....	40
3.3.11	Exposure assessment.....	41
3.3.11.1	Exposure-related effects on severity and persistence	42
3.3.11.2	Exposure timing and susceptibility	42
3.3.11.3	Route of exposure and local immunity	43
3.3.11.4	Exposure and toxicokinetic considerations.....	43
3.3.12	Risk characterization.....	44
3.4	Entry points for immunotoxicity risk assessment.....	45
4.	ASSESSMENT OF IMMUNOSUPPRESSION	49
4.1	Introduction.....	49
4.2	Hazard identification.....	49
4.3	Hazard characterization	50
4.4	Clinical and epidemiological data.....	50
4.4.1	Clinical data	50
4.4.2	Epidemiological data	50
4.5	Laboratory animal data	51
4.6	Local versus systemic effects.....	53
4.7	(Ir)reversibility of effects.....	54
4.8	Biological plausibility.....	54
4.8.1	Weight of evidence approach for assessment of immunosuppression.....	55
4.8.2	Biological relatedness of different outcomes.....	60
4.8.2.1	Diseases associated with specific types of immunosuppression in humans	60
4.8.2.2	Diseases associated with specific types of immunosuppression in laboratory animals.....	62
4.8.3	Adversity and significance of mild to moderate immunosuppression.....	64
4.8.4	Mode of action/mechanisms	66
4.9	Dose–response relationships and thresholds.....	66
4.10	Groups at risk (developing immune system, elderly, immunocompromised).....	67
4.11	Acute versus chronic exposure	68
4.12	Uncertainty factors.....	69
4.12.1	Intraspecies uncertainty factor	69

4.12.2	Interspecies uncertainty factor	69
4.12.3	Database uncertainty factor.....	69
4.13	Exposure assessment.....	70
4.13.1	Exposure-related effects on severity and persistence	70
4.13.2	Exposure timing and susceptibility	71
4.14	Risk characterization in terms of reduced resistance to infections or tumours.....	72
5.	ASSESSMENT OF IMMUNOSTIMULATION.....	73
5.1	Introduction.....	73
5.2	Hazard identification.....	73
5.3	Hazard characterization	74
5.4	Clinical and epidemiological data.....	75
5.5	Laboratory animal data	76
5.5.1	Vaccination	76
5.5.2	Heavy metals.....	77
5.5.3	Pesticides.....	78
5.5.4	Endocrine disruptors	79
5.5.5	Drugs.....	80
5.5.6	Air pollutants and other examples	80
5.6	Local versus systemic effects	81
5.7	(Ir)reversibility of effects.....	81
5.8	Biological plausibility.....	81
5.8.1	Weight of evidence approach for assessment of immunostimulation	82
5.8.2	Mode of action/mechanisms	87
5.9	Groups at risk (developing immune system, elderly, allergic/autoimmune patients).....	88
5.10	Dose–response relationships and thresholds	89
5.11	Acute versus chronic exposure	90
5.12	Uncertainty factors	90
5.13	Exposure assessment	90
5.14	Risk characterization.....	90
6.	ASSESSMENT OF SENSITIZATION AND ALLERGIC RESPONSE.....	92
6.1	Introduction.....	92
6.2	Hazard identification.....	93
6.3	Hazard characterization (quantitative dose–response analysis).....	94
6.3.1	Skin sensitization	95
6.3.1.1	Clinical and epidemiological data.....	95
6.3.1.2	Laboratory animal data	97
6.3.1.3	In vitro data and general sensitization threshold approach.....	99
6.3.2	Respiratory sensitization.....	100
6.3.2.1	Clinical and epidemiological data.....	102
6.3.2.2	Laboratory animal data	104
6.3.3	Oral and parenteral sensitization.....	106
6.3.3.1	Clinical and epidemiological data.....	108
6.3.3.2	Laboratory animal data	109
6.3.3.3	Pseudoallergic reactions.....	109
6.3.4	Derivation of point of departure	110

6.4	Biological plausibility	112
6.4.1	Weight of evidence approach for assessment of sensitization	112
6.4.2	Mode of action/mechanisms	117
6.5	Uncertainty factors	119
6.5.1	Interspecies uncertainty factor	119
6.5.2	Intraspecies uncertainty factor	120
6.5.2.1	Genetic effects	121
6.5.2.2	Inherent barrier function	121
6.5.2.3	Sex	122
6.5.2.4	Ethnicity	122
6.5.2.5	Age	122
6.5.2.6	Summary	122
6.5.3	Matrix factor	123
6.5.3.1	Irritants	123
6.5.3.2	Penetration enhancers	123
6.5.4	Use and time factor	124
6.5.4.1	Site of contact	124
6.5.4.2	Barrier integrity	125
6.5.4.3	Occlusion	125
6.5.4.4	Frequency of exposure (time extrapolation)	125
6.5.5	Database uncertainty factor	126
6.6	Groups at risk (developing immune system, elderly, immunocompromised)	126
6.7	Derivation of acceptable exposure level	127
6.8	Exposure assessment	127
6.9	Risk characterization	128
7.	ASSESSMENT OF AUTOIMMUNITY AND AUTOIMMUNE DISEASE	131
7.1	Introduction	131
7.2	Hazard identification	131
7.3	Hazard characterization	133
7.4	Clinical and epidemiological data	133
7.5	Laboratory animal data	134
7.6	(Ir)reversibility of effects	134
7.7	Biological plausibility	135
7.7.1	Weight of evidence approach to assessment of risk for autoimmunity	135
7.7.2	Mode of action/mechanisms	139
7.8	Life stage considerations and groups at risk	141
7.9	Dose–response relationships and thresholds	142
7.10	Uncertainty factors	144
7.10.1	Genetic susceptibility	144
7.11	Exposure assessment	145
7.12	Risk characterization	146
	REFERENCES	147
	GLOSSARY	181

ANNEXES	185
Annex 1 Selection of national and European requirements and guidelines	186
Annex 2 Selection of WHO/IPCS guidance on chemical risk assessment.....	187
CASE-STUDIES	188
Case-study 1 Assessment of immunosuppression caused by lead exposure	189
Case-study 2 Assessment of immunostimulation induced by hexachlorobenzene	215
Case-study 3 Assessment of sensitization and allergic response to halogenated platinum salts	229
Case-study 4 Assessment of skin sensitization to citral	245
Case-study 5 Assessment of mercury-related autoimmunity and autoimmune disease	268
Case-study 6 Assessment of autoimmunity-stimulating effect of trichloroethylene.....	293

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_28577

